DEXONE 0.75
Clinical safety rating: caution
Comprehensive clinical and safety monograph for DEXONE 0.75 (DEXONE 0.75).
Dexamethasone is a potent glucocorticoid that binds to glucocorticoid receptors, modulating gene expression to inhibit pro-inflammatory cytokines (e.g., IL-1, IL-6, TNF-α) and reduce inflammation, immune response, and adrenal function.
| Metabolism | Primarily hepatic via CYP3A4; also undergoes 11β-hydroxysteroid dehydrogenase conversion. |
| Excretion | Renal: ~65-80% as unchanged drug; Fecal: ~10-15% as metabolites; Minor biliary excretion. |
| Half-life | Terminal elimination half-life: 36-54 hours in adults with normal renal function; prolonged to 72-168 hours in severe renal impairment. |
| Protein binding | ~80% bound to albumin and cortisol-binding globulin (CBG). |
| Volume of Distribution | Vd: 1.0-1.5 L/kg; indicates extensive tissue distribution. |
| Bioavailability | Oral: 85-95% (well absorbed). |
| Onset of Action | Oral: 1-2 hours; IV: 15-30 minutes; IM: 30-60 minutes. |
| Duration of Action | Oral: 24-36 hours (symptom relief); IV: 12-24 hours (hemodynamic effects); Clinical note: Taper to avoid adrenal insufficiency. |
| Molecular Weight | 416.47 Da |
0.75 mg orally once daily, typically as part of a tapering regimen for anti-inflammatory or immunosuppressive effects.
| Dosage form | TABLET |
| Renal impairment | No dose adjustment required for renal impairment; drug is primarily hepatically metabolized. |
| Liver impairment | Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: avoid use or reduce dose by 75% with monitoring. |
| Pediatric use | 0.02-0.3 mg/kg/day orally divided every 6-12 hours; maximum 0.75 mg/day. Dosing based on indication and response. |
| Geriatric use | Start at lowest effective dose (e.g., 0.375 mg once daily) and titrate slowly due to increased risk of osteoporosis, hyperglycemia, and immunosuppression. |
| 1st trimester | Associated with increased risk of orofacial clefts; use only if benefit outweighs risk. |
| 2nd trimester | Use may cause fetal adrenal suppression; monitor growth and amniotic fluid. |
| 3rd trimester | Use may cause neonatal adrenal suppression; avoid prolonged use near term. |
Clinical note
Comprehensive clinical and safety monograph for DEXONE 0.75 (DEXONE 0.75).
| Placental transfer | Readily crosses placenta; fetal levels 10-30% of maternal levels. |
| Breastfeeding | Enters breast milk; monitor infant for adrenal suppression and growth. Use lowest effective dose. |
| Lactation Rating | L3 (Moderately Safe) |
■ FDA Black Box Warning
No FDA boxed warning exists for dexamethasone.
| Serious Effects |
Systemic fungal infectionHypersensitivity to dexamethasone or componentsAdministration of live or live-attenuated vaccines
| Precautions | Increased risk of infections due to immunosuppression, Hypothalamic-pituitary-adrenal axis suppression, Exacerbation of systemic fungal infections, Increased risk of gastrointestinal perforation or bleeding, Osteoporosis with prolonged use, Cushing's syndrome with high doses, Ocular effects: glaucoma, cataracts, Vaccination risk: live vaccines may cause disseminated infection, Use in pregnancy: risk of fetal harm |
| Food/Dietary | Grapefruit and grapefruit juice may increase dexamethasone levels; avoid concurrent use. Limit sodium intake to reduce fluid retention. Potassium-rich foods may be beneficial; monitor potassium if on diuretics. |
Loading safety data…
| Teratogenic Risk | DEXONE (dexamethasone) is a corticosteroid. First trimester: Increased risk of cleft lip/palate (odds ratio ~3.4). Second/third trimester: Fetal growth restriction, adrenal suppression, premature birth. Chronic exposure may cause HPA axis suppression in neonate. |
| Fetal Monitoring | Maternal: Blood pressure, blood glucose, serum electrolytes, signs of infection. Fetal: Ultrasound for growth restriction (every 4-6 weeks if prolonged use), fetal heart rate monitoring if preterm labor. Neonatal: Observe for adrenal insufficiency if maternal use near delivery. |
| Fertility Effects | May inhibit ovulation by suppressing pituitary-adrenal axis; reversible upon discontinuation. No evidence of permanent fertility impairment in males or females. |
| Clinical Pearls | DEXONE 0.75 contains dexamethasone 0.75 mg. Equivalent anti-inflammatory dose: 0.75 mg dexamethasone = 5 mg prednisone. Long-acting glucocorticoid with minimal mineralocorticoid activity; useful for cerebral edema and COVID-19. Taper to avoid adrenal insufficiency. Monitor for hyperglycemia, especially in diabetics. Avoid live vaccines. |
| Patient Advice | Take exactly as prescribed; do not stop suddenly without consulting your doctor. · May cause increased appetite, weight gain, or fluid retention. · Report any signs of infection (fever, sore throat) or unusual bruising/bleeding. · Avoid live vaccines (e.g., MMR, nasal flu) while on this medication. · Carry a steroid warning card or medical alert ID. · Do not take with NSAIDs (ibuprofen, naproxen) unless directed by your doctor. |